KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Assets: 2013-2025

Historic Non-Current Assets for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $127.7 million.

  • Xenon Pharmaceuticals' Non-Current Assets fell 27.55% to $127.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.7 million, marking a year-over-year decrease of 27.55%. This contributed to the annual value of $162.9 million for FY2024, which is 49.08% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Non-Current Assets stood at $127.7 million for Q3 2025, which was down 26.62% from $174.0 million recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Non-Current Assets peaked at $319.8 million during Q4 2023, and registered a low of $7.4 million during Q1 2021.
  • Its 3-year average for Non-Current Assets is $179.4 million, with a median of $174.0 million in 2025.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Non-Current Assets skyrocketed by 1,475.28% in 2022 and then crashed by 49.08% in 2024.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Non-Current Assets stood at $13.0 million in 2021, then soared by 1,084.63% to $153.8 million in 2022, then spiked by 107.89% to $319.8 million in 2023, then crashed by 49.08% to $162.9 million in 2024, then decreased by 27.55% to $127.7 million in 2025.
  • Its Non-Current Assets stands at $127.7 million for Q3 2025, versus $174.0 million for Q2 2025 and $177.7 million for Q1 2025.